PALSONIFY logo
palsonify logo
PALSONIFY logo

Clinical data

Finally, consistent control in a pill1

Powerful efficacy you never thought possible in a pill1

Icon of a clock

Rapid and reliable biochemical control1

Lowered IGF-1 in 2 to 4 weeks in patients with uncontrolled acromegaly. Maintained IGF-1 control in patients switching from SRLs

Icon of two arrows rotating clockwise

Consistent symptom control1

Overall reduction in symptom severity vs a worsening of symptoms with placebo

Icon of a bar graph

Sustained IGF-1 control10

IGF-1 control maintained for more than a year in ongoing uncontrolled open-label studies

  • IGF-1=insulin-like growth factor 1; SRLs=somatostatin receptor ligands.

Acromegaly control achieved across a range of patients1

In patients switching from iSRLs and those who were biochemically uncontrolled, including treatment naïve, PALSONIFY provided reliable, consistent, and sustained biochemical and symptom control.1

Image of Megan, a real acromegaly patient walking with a friend.

Megan,

taking PALSONIFY

PATHFNDR-1 CLINICAL TRIAL

PALSONIFY seamlessly maintained IGF-1 control in patients who switched from SRL injections (octreotide or lanreotide).1

View clinical data

PATHFNDR-2 CLINICAL TRIAL

PALSONIFY proved effective in patients who were biochemically uncontrolled, including treatment naïve.1

View clinical data

  • iSRLs=injected somatostatin receptor ligands.